Preventing Suicide and Suffering
Please help people who are suffering with mental illness by supporting the development of psychedelic-assisted psychotherapy in Australia.
Mind Medicine Australia (MMA) is a charity that seeks to alleviate the suffering caused by mental illness in Australia through expanding the treatment options available to medical practitioners and their patients. We are focused on the development of safe and effective psychedelic-assisted therapies to cure a range of mental illnesses.
Accessing Psilocybin & MDMA-Assisted Therapy in Australia
Psilocybin and MDMA are now classified as medicines in Australia!
In February 2023 the TGA approved Mind Medicine Australia's application to reschedule psilocybin and MDMA from Schedule 9 (prohibited substances) to Schedule 8 (controlled medicines) of the Poisons Standard. With this rescheduling, psychiatrists who are given approval from the TGA are now able to prescribe psilocybin for treatment-resistant depression and MDMA for PTSD. These changes came into effect July 1st, 2023.
Apply now for our Certificate in Psychedelic-Assisted Therapies (CPAT)
Mind Medicine Australia has secured a supply agreement with Optimi Health for MDMA and psilocybin. This agreement will ensure Australian psychiatrists and researchers have affordable access to GMP grade medicines for clinical trials and the TGA's Authorised Prescriber Scheme, which begins from July 1st 2023.
Registered health professionals and researchers are invited to reach out to learn more. Click below.
Everyone in need should be able to access psychedelic-assisted therapies in medically controlled environments
#1 Psilocybin and MDMA Rescheduled in Australia - a world first!
$15m Federal Government Funding Secured for Innovative Therapies for Mental Illness
3 Clinical Trials Supported
240+ Therapists trained
600K+ YouTube views
33+ Local chapters
250+ Events to date reaching tens of thousands of people
2600+ Chapter members
80+ Advisory panel members
32,500+ Volunteer hours
- Around the world psychedelic-assisted therapies are on the cusp of widespread acceptance as a breakthrough therapy for key classes of mental illness.
- These medicines have been shown to be very safe and non-addictive when used in a medically controlled environment.
- These therapies are being trialed as treatments for depression, PTSD, anxiety, end-of-life distress, dementia, anorexia and opioid, alcohol and smoking addictions and a number of other illnesses.
- These treatments are showing remission rates of up to 80% after just 2-3 medicinal doses in combination with psychotherapy.
- There have been over 300+ trials in the past decade.
- In the 50's/60's these medicines were considered the next big breakthrough in treatments for mental illnesses before the War on Drugs in 1970, which stopped further research for decades.
- Both psilocybin-assisted psychotherapy for major and treatment-resistant depression as well as MDMA-assisted psychotherapy for PTSD have been granted “Breakthrough Therapy Designation” by the Food and Drug Administration (FDA) in the USA to fast-track the approval process because clinical evidence to date indicates that they may demonstrate substantial improvement over currently available therapies.
- In the past 2 years over 40 for-profit companies have emerged in this space globally creating an entire new industry, jobs and other opportunities for innovation in treatments.
- In February 2023 the TGA rescheduled MDMA and psilocybin, making Australia the first country in the world to recognise them as medicines.
Your donation supports:
Financial Assistance Toward Practitioner Professional Development
Supporting access for practitioners to build upon their skills. This includes MMI's Certificate in Psychedelic-Assisted Therapies program, as well as shorter workshops to prepare mental health professionals for the future.
Awareness and Knowledge Building
We organise educational events, film screenings, conferences and also have local chapters open to the public.
Access to Medically Approved Therapy
We promote changes in legislation, promote legal and ethical frameworks, provide psychological support services, develop clinical rollouts and medicine manufacturing capabilities.
Engagement with University sector and novel research
Engagement with universities to promote research, development and economic analysis and rollout plans.
Supporting those who cannot afford treatments
Mind Medicine Australia will be setting up a special fund to receive donations from large to small philanthropists, and hopefully governments around Australia, to support those who cannot afford the full costs of treatments.